Background: The global distribution of IBS is surprisingly uniform, affecting men and women of all ages. Its deep-rooted character, symptoms that fluctuate from moderate to extreme, have several detrimental effects on the sufferer's standard of living; consequently, proper treatment of these patients is necessary. The etiology of IBS is unknown. Although several explanations were also proposed, the specific etiology of irritable bowel syndrome remains unknown. Clinical trials using stabilized therapies and new active medications have shown symptom reduction over placebo. Objective: IBS has long been linked to visceral sensitivity and gastrointestinal motor abnormalities. The pathophysiology of IBS appears to be multifaceted. However, several of the following elements are vital in forming IBS. This paper aims to provide a complete, scientific proof assessment of the prognosis, pathogenesis, and therapy choices to assist clinicians in successfully treating their patients. Method: The report's information was compiled by combining numerous review articles and research papers from multiple sources, including Hindawi, Elsevier, NCBI [National Centre for Biotechnology Information], and Research Gate, from 1981 to 2021, using keywords such as IBS, Brain-gut axis, postinfectious IBS, Microbiota, low-grade inflammation, and so on. Conclusion: The acute symptom influences the selection of medical techniques and therapy (IBS with diarrhoea, IBS with constipation, or mixed IBS). Current research demonstrates both pharmaceutical and non-pharmaceutical treatment has a positive impact (in comparison to a placebo) on irritable bowel syndrome (IBS) problems, discomfort relief, and improved health status.
Read full abstract